Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: Long-term follow-up of patients treated on Children's Cancer Group trial 1881

Journal of Clinical Oncology

Volumn 21, Issue 9, 2003, Pages 1790-1797

  Hutchinson, Raymond J ^a   Gaynon, Paul S ^a   Sather, Harland ^a   Bertolone, Salvatore J ^a   Cooper, Herbert A ^a   Tannous, Raymond ^a   Wells, Linda M ^a   Heerema, Nyla A ^a   Sailer, Scott ^a   Trigg, Michael E ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER THERAPY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ACUTE LYMPHOCYTIC LEUKEMIA; DOSE RESPONSE; DRUG ADMINISTRATION; MULTICENTER STUDY; PATHOLOGY; PRESCHOOL CHILD; RECURRENT DISEASE; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SURVIVAL; TREATMENT OUTCOME;

EID: 0038811747     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.03.009     Document Type: Article

References (22)

1. Pui CH: Acute lymphoblastic leukemia in children. Curr Opin Oncol 12:3-12, 2000
2. Smith M, Arthur D, Camitta B, et al: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14:18-24, 1996
3. Gaynon PS, Desai AA, Bostrom BC, et al: Early response to therapy and outcome in childhood acute lymphoblastic leukemia: A review. Cancer 80:1717-1726, 1997
4. Goldie J, Coldman A: The genetic origin of drug resistance in neoplasms: Implications for systemic therapy. Cancer Res 44:3643-3653, 1984
5. Bleyer WA, Sather HN, Nickerson HJ, et al: Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: A report of the CCG-161 study by the Children's Cancer Study Group. J Clin Oncol 9:1012-1021, 1991
6. Tubergen D, Gilchrist G, O'Brien A, et al: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features. J Clin Oncol 11:527-537, 1993
7. Henze G, Langermann HJ, Bramswig J, et al: The BFM 76/79 acute lymphoblastic leukemia therapy study. Klin Padiatr 193:145-154, 1981
8. Henze G, Langermann HJ, Fengler R, et al: Therapy study BFM 79/81 for treatment of acute lymphoblastic leukemia in children and adolescents: Intensified reinduction therapy for patients with different risks of relapse. Klin Padiatr 194:195-203, 1982
9. Henze G, Fengler R, Reiter A, et al: Impact of early intensive reinduction therapy on event-free survival in children with low-risk acute lymphoblastic leukemia. Haematol Blood Transfus 33:483-488, 1990
10. Reiter A, Schrappe M, Ludwig WD, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133, 1994
11. Gaynon P, Qu R, Chappell R, et al: Survival after relapse in childhood acute lymphoblastic leukemia: Impact of site and time to first relapse, the Children's Cancer Group experience. Cancer 82:1387-1395, 1998
12. Steinherz PG, Siegel SE, Bleyer WA, et al: Lymphomatous presentation of childhood acute lymphoblastic leukemia. Cancer 68:751-758, 1991
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
14. Breslow N: Analysis of survival data under the proportional hazards model. Int Stat Rev 43:45-58, 1975
15. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977
16. Richards S, Burrett J, Hann I, et al: Improved survival with early intensification: Combined results from the Medical Research Council childhood ALL randomized trials, UKALL X and UKALL XI-Medical Research Council Working Party on Childhood Leukaemia. Leukemia 12:1031-1036, 1998
17. Hann I, Vora A, Richards S, et al: Benefit of intensified treatment for all children with acute lymphoblastic leukemia: Results from MRC UKALL XI and MRC ALL97 randomized trials. Leukemia 14:356-363, 2000
18. Gaynon P, Bostrom B, Hutchinson R, et al: Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies. J Clin Oncol 19:1916-1925, 2001
19. Miller DR, Leikin S, Albo V, et al: Use of prognostic factors in improving the design and efficiency of clinical trials in childhood leukemia: Children's Cancer Study Group report. Cancer Treat Rep 64:381-392, 1980
20. Nachman JB, Sather HN, Sensel MG, et al: Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338:1663-1671, 1998
21. Stork L, Sather H, Nachman J, et al: Intensive therapy 'rescues' children with standard risk ALL (SR-ALL) and slow early response to induction: CCG-1952 results. Blood 96:466a, 2000 (abstr 2007)
22. Lange BJ, Bostrom BC, Cherlow JM, et al: Double delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 99:825-833, 2002